Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.31 |
| ▸ | PTGFR | P43088 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085022 | 0.92 | TBXA2R (0.41) | ALDH1A1TBXA2RPTGFR | |
| SCHEMBL7099597 | 0.88 | KDM4E (0.44) | ALDH1A1TBXA2R | |
| SCHEMBL6085559 | 0.85 | CNR2 (0.36) | ALDH1A1PTGFR | |
| SCHEMBL6092808 | 0.85 | — | — | |
| SCHEMBL6086811 | 0.82 | PTGFR (0.37) | TBXA2RPTGFR | |
| SCHEMBL6085069 | 0.75 | TBXA2R (0.39) | ALDH1A1TBXA2RPTGFR | |
| SCHEMBL6084756 | 0.74 | TBXA2R (0.47) | ALDH1A1TSHRTBXA2RPTGFR | |
| SCHEMBL6086678 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TBXA2R | |
| SCHEMBL6085363 | 0.74 | TBXA2R (0.39) | ALDH1A1TSHRTBXA2RPTGFR | |
| SCHEMBL6692631 | 0.72 | PTGFR (0.46) | ALDH1A1TSHRTBXA2RPTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109571-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2003-06-12 | — | — | US | claimed |
| EP-0737185-B1 | 7-[CARBOXYALKYL OR ALKENYL]-6-[ALKYL OR ALKENYL] 3-OXO-2,4-DIOXOBICYCLO-[3.2.1] OCTANE AND DERIVATIVES THEREOF | ALLERGAN INC (US) | 1999-03-31 | — | — | EP | claimed |
| US-7019149-B2 | Thromboxane ligands without blood clotting side effects | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2005-03-03 | — | — | US | disclosed |
| US-5516791-A | VISION DEFECTS FOR TREATMENT OF HYPERTENSION OF EYES | ALLERGAN (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, OXTR | ALDH1A1 1904/4885TSHR 106/4885TBXA2R 2/4885 |
| US-20030109571-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, CBR1 | ALDH1A1 1908/4885TSHR 206/4885TBXA2R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.